top of page

Chase Norfleet

B2B go-to-market strategy and channel activation.

Chase Norfleet leads bioDesign Group's B2B go-to-market strategy, brand development, and channel activation. He is building the marketing infrastructure, institutional prospect pipeline, and pharma co-packaging outreach programs in advance of the Q1 2027 commercial launch of STiK and SkinClip. Full bio to be updated.

Chase Norfleet

Where We Are Today.

FDA PATHWAY

510(k)

PROTOTYPES

In Development

DISTRIBUTION

B2B, B2C Channels

GLOBAL MARKETS

Planning

EU · UK · Canada · Australia
India — 2028–2029

steve holds forth.png
leonard cut plastic.png
human factors test.jpeg
LED test.JPG
IMG_0266.JPG
delivery.JPG
IMG_3859.JPG
STiK packaging.png

Let's Build Something That Matters.

Whether you’re in Pharma, hospital systems, medical supplies, ISO 13485 manufacturing, a first responder, a pro caregiver, or a parent who wants to give their child a shot at home, we’d love to hear from you.

Subject (select option below)
Screen Shot 2026-03-10 at 7.33.59 AM_clipped_rev_1.png

© Copyright TM bioDesign Group Technologies Inc. / Patented & patents pending. All rights reserved.

Site Optimization By ACW Client Services.

bottom of page